Neurocrine Biosciences Inc. (NYSE: NBIX) announced on August 21, 2007, that the FDA accepted resubmission of its New Drug Application (NDA) for indiplon for the treatment of insomnia and has set a Prescription Drug User Fee Act action date of December 12, 2007. NBIX December option implied volatility is at 122, January is at 101. NBIX average option implied volatility over the last 26-weeks is 81 according to Track Data, suggesting larger winter price risks.
Daily options Update is provided by Stock Specialist Paul Foster of theflyonthewall.com.
Before the bell: Futures higher ahead of housing, jobless data
Nuclear power is on the comeback trail
Apple backs AT&T in continuing spat with Verizon
